Navigation Links
Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
Date:6/30/2011

TOKYO, June 30, 2011 /PRNewswire/ --

  • GLOW2 Study Shows NVA237 Provides Superior24-hour Bronchodilation to Placebo (p<0.001) with Comparable Efficacy to Open-Label Tiotropium at 12 Weeks
  • NVA237 Shown to be Well-Tolerated in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
  • Phase III data Support First Regulatory Submission by Novartis for NVA237 by end of 2011


 

Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), announces that results reported today by Novartis from the pivotal Phase III GLOW2 clinical trial show that once-daily NVA237 (glycopyrronium bromide) 50 mcg significantly improved lung function in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) relative to placebo (p<0.001), with similar efficacy to open-label tiotropium.

Further efficacy and safety results from GLOW2 will be presented at a scientific congress in 2012, and the data will be used to support an application for regulatory approval to be filed before the end of 2011.

Mr Shinichi Tamura, CEO of Sosei, said: "GLOW2 is the second NVA237 Phase III study to meet its primary end point and further endorses the benefit of NVA237 in COPD patients.  We look forward to Novartis filing the product in 2011, followed by the filing of QVA149, the fixed-dose combination of NVA237 and indacaterol, expected to occur in 2012 ."

In an exploratory arm of the study, NVA237 was compared with open-label tiotropium (Spiriva® HandiHaler[® Spiriva® and HandiHaler® are registered trademarks of Boehringer Ingelheim Pharma GmbH & Co. KG.]) 18 mcg, another once-daily long-acting muscarinic antagonist (LAMA) indicated for the treatment of COPD. Results show that NVA237 produced similar improvements in lung function to tiotropium.

The study met its
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
2. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
3. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
4. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
5. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
6. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
7. Glycotex, Inc. Releases Final Phase II Clinical Trials Results in the Clinicaltrials.gov Database and Announces the Results of the Mechanism of Action Study for its Product Candidate GLYC-101
8. Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction
9. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
10. Once-Monthly Exenatide Improved Glucose Control in Patients with Type 2 Diabetes: Phase 2 Study Results Presented at ADA 2011
11. New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... -- Hospira, Inc. (NYSE: HSP ), ... spoke about the importance of extrapolation in bringing biosimilars ... annual European Biosimilars Group conference in London ... publication of a pivotal white paper titled, "Why ... biosimilars." Speaking at the EGA conference, ...
(Date:4/23/2015)... , April 24, 2015  AbbVie (NYSE: ABBV ... Administration (FDA) has accepted its New Drug Application (NDA) ... two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), ... of adults with chronic genotype 4 (GT4) hepatitis C ... first all-oral, interferon-free therapy being evaluated by the FDA ...
(Date:4/23/2015)... 23, 2015 Once again, BeaconMedaes is meeting ... to patient safety. BeaconMedaes, priority is to ... disease. The next generation Zone Valve Box ... are now mounted in the assembly, allowing for ease ... ceiling tiles potentially releasing dust spores and other bacteria ...
Breaking Medicine Technology:Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 3Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 4Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 5Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 7U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7BeaconMedaes launches new Zone Valve Box Assembly 2
(Date:4/26/2015)... Indiana Fiber Network, LLC (IFN), the ... Mutual Insurance Company has selected IFN as a fiber ... at Brotherhood Mutual Insurance Company states: “IFN’s broadband fiber ... Mutual needed. We were interested in building ... us to ensure we achieved both. ” ...
(Date:4/26/2015)... India Network Foundation, a non-profit organization ... services to the Asian Indian community in the United ... more than two decades. The India News Network Digest ... around the world with the latest news items from ... Immigration Law Forum Digest, edited and contributed by Sheela ...
(Date:4/26/2015)... 2015 The grand celebration got off to ... Dettor, CCAR’s Managing Director. Deb then introduced Sandy Valentine, the ... in attendance because of his Walk for Recovery ... able to express his gratitude to the volunteers via video. ... dedication to carrying out CCAR’s mission. Volunteer Manager Conrad ...
(Date:4/25/2015)... Francisco, California (PRWEB) April 26, 2015 ... his search for original 1965 Rolling Stones Greensboro Coliseum concert ... and was part of the Stone's Second American Tour. ... by Globe Poster Company out of Baltimore, Maryland. This ... in the northeast and southern cites. Globe uses garish ...
(Date:4/25/2015)... York, New York (PRWEB) April 25, 2015 ... ) established for vaginal mesh lawsuits filed against ... the U.S. District Court, Southern District of West ... 9th, a Scheduling Conference was convened that day, ... Plaintiffs’ Master Long Form Complaint. The Order directed ...
Breaking Medicine News(10 mins):Health News:Brotherhood Mutual Insurance Company Selects Indiana Fiber Network, LLC for Fiber Transport Service 2Health News:Brotherhood Mutual Insurance Company Selects Indiana Fiber Network, LLC for Fiber Transport Service 3Health News:North American Telugu Society Bestows Community Service Award to India Network Foundation for Its Generosity and Sponsor of Visitor Health Insurance to Indian Visitors 2Health News:North American Telugu Society Bestows Community Service Award to India Network Foundation for Its Generosity and Sponsor of Visitor Health Insurance to Indian Visitors 3Health News:The Connecticut Community for Addiction Recovery (CCAR) honors its volunteers during National Volunteer Recognition Week. 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 3Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 4
... taken on time , , WEDNESDAY, May 7 (HealthDay News) -- ... miss doses when reminded by an electronic pillbox that both ... of pills to take and how to take them, new ... National Institute on Aging, was presented recently at the American ...
... SPOKANE, Wash., May 7 MIPSolutions, Inc. (OTC,Bulletin ... the,University of Utah has revealed a significant development ... that Molecularly Imprinted,Ionomer (MII) beads imprinted to retain ... This translates into decreased development,time, a large amount ...
... in Spanish and Chinese . ... translational research grant program will fund a pilot ... appropriate and improved diabetes care in rural communities ... Diabetes Self-Management Program (DSME), will help Filipinos with ...
... DaVita Inc. (NYSE:,DVA) announced that its Board ... current stock repurchase program. The increase, together ... $250,000,000 of,the Company,s common stock. The stock ... http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO ), Rich Whitney, CFO, ...
... May 7 Vaccinogen Inc. said Dutch health,authorities licensed ... clearing the path to more than $100 million of,potential ... facility based in Emmen, The,Netherlands also paves the way ... the final step before the vaccine can be sold ...
... Despite a weakened economy, a,challenging airline industry, and ... summer vacation plans, travel industry experts,observe; but they ... ), Jim Grace, President and CEO of ... "At InsureMyTrip.com, we are,seeing noticeable changes in the ...
Cached Medicine News:Health News:Electronic Pillbox Helps Seniors Stick to Drug Regimens 2Health News:Electronic Pillbox Helps Seniors Stick to Drug Regimens 3Health News:MIPSolutions, Inc. Reduces Expense and Development Time Associated With Precious Metal Extraction 2Health News:International Diabetes Federation gives grant to Philippine diabetes education program 2Health News:Dutch Authorize Manufacture of Vaccinogen's New Cancer Vaccine; License Clears Path to European Production, Final FDA Trial 2Health News:InsureMyTrip.Com's Travel Insurance Tips for Protecting Your Summer Vacation 2Health News:InsureMyTrip.Com's Travel Insurance Tips for Protecting Your Summer Vacation 3
... The BIOM 3 (Binocular Indirect Ophthalmo-Microscope) incorporates ... microscope and enables a view of up to ... the BIOM 3 the eye may be rotated ... easily viewed. Even surgery through small pupils ...
... The Philips HeartStart Home Defibrillatorthe latest ... than 175,000 devices deployed, Philips is ... defibrillators on airplanes, and in airports, ... HeartStart Home Defibrillator is the first ...
... custom bars have a large body ... contacts (spaced 3 centimeters center-to-center) to ... repeated cleaning. Polarity indicators are molded ... handle fits our bar electrode styles. ...
... custom bars have a large body ... contacts (spaced 3 centimeters center-to-center) to ... repeated cleaning. Polarity indicators are molded ... handle fits our bar electrode styles. ...
Medicine Products: